BR112019004639A2 - formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmas - Google Patents
formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmasInfo
- Publication number
- BR112019004639A2 BR112019004639A2 BR112019004639A BR112019004639A BR112019004639A2 BR 112019004639 A2 BR112019004639 A2 BR 112019004639A2 BR 112019004639 A BR112019004639 A BR 112019004639A BR 112019004639 A BR112019004639 A BR 112019004639A BR 112019004639 A2 BR112019004639 A2 BR 112019004639A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulations
- producing
- taste
- thione
- dithiol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
esta divulgação fornece, dentre outros elementos, composições que compreendem quantidades de cristais oltipraz, assim como método para produzir tais composições, e método para tratar pacientes com o uso de tais composições. composições de gosto modificado também são fornecidas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201611031045 | 2016-09-12 | ||
IN201611031046 | 2016-09-12 | ||
US201662412701P | 2016-10-25 | 2016-10-25 | |
PCT/IB2017/001231 WO2018047002A1 (en) | 2016-09-12 | 2017-09-12 | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019004639A2 true BR112019004639A2 (pt) | 2019-07-16 |
Family
ID=60569946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019004639A BR112019004639A2 (pt) | 2016-09-12 | 2017-09-12 | formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmas |
Country Status (9)
Country | Link |
---|---|
US (2) | US11185544B2 (pt) |
EP (1) | EP3509641A1 (pt) |
JP (2) | JP2019533008A (pt) |
KR (1) | KR20190089851A (pt) |
CN (1) | CN109996563A (pt) |
AU (1) | AU2017322544B2 (pt) |
BR (1) | BR112019004639A2 (pt) |
CA (1) | CA3036630A1 (pt) |
PH (1) | PH12019500530A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019531344A (ja) * | 2016-09-12 | 2019-10-31 | エスティー アイピー ホールディング エージー | 4−メチル−5−(ピラジン−2−イル)−3h−1,2−ジチオール−3−チオンの処方物、ならびにそれらの製造方法及び使用方法 |
US11260604B2 (en) * | 2018-03-14 | 2022-03-01 | Andrew Reynolds | Method and system for dispensing molten wax into molds by means of a desktop apparatus |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
EP1280556A1 (en) | 2000-05-05 | 2003-02-05 | Wisconsin Alumni Research Foundation | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
US7012148B2 (en) | 2001-09-25 | 2006-03-14 | Trustees Of Dartmouth College | Compositions and methods for thionation during chemical synthesis reactions |
US7199122B2 (en) | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
AU2003202763A1 (en) | 2002-02-13 | 2003-09-04 | Solvay Pharma | Use of anethole dithiolethione in lung cancer chemoprevention |
KR100491318B1 (ko) | 2002-11-26 | 2005-05-24 | 씨제이 주식회사 | 올티프라즈(Oltipraz) 제조방법 |
KR20050014960A (ko) * | 2003-08-01 | 2005-02-21 | 씨제이 주식회사 | B형 간염 치료 및 간 조직 재생용 약제학적 조성물 |
BRPI0417987A (pt) | 2003-12-22 | 2007-04-27 | Alcon Inc | agentes para o tratamento de retinopatia glaucomatosa e de neuropatia óptica |
KR100629771B1 (ko) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
MX2007006233A (es) * | 2004-11-24 | 2007-11-23 | Medpointe Healthcare Inc | Composiciones que comprenden azelastina y metodos de uso de la misma. |
FR2879444B1 (fr) | 2004-12-22 | 2007-05-18 | Oreal | Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie |
US20070036733A1 (en) | 2005-08-12 | 2007-02-15 | Takasago International Corp. (Usa) | Sensation masking composition |
BRPI0616821B1 (pt) | 2005-08-15 | 2022-06-07 | Givaudan Sa | Método para proporcionar um efeito refrescante em um produto e produto possuindo um efeito refrescante |
US7803353B2 (en) | 2006-03-29 | 2010-09-28 | The Procter & Gamble Company | Oral care compositions having improved consumer aesthetics and taste |
GB0704718D0 (en) | 2007-03-12 | 2007-04-18 | Prendergast Patrick T | Compounds and methods for preventing and treating mucositis |
WO2008151460A2 (en) | 2007-06-13 | 2008-12-18 | Givaudan Sa | Cooling compounds |
US20110003747A1 (en) | 2007-07-20 | 2011-01-06 | Coloumbe Pierre A | Use of nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
WO2009099830A2 (en) | 2008-01-31 | 2009-08-13 | Mcneil-Ppc, Inc. | Edible film-strips for immediate release of active ingredients |
WO2009114525A1 (en) | 2008-03-10 | 2009-09-17 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
US8858995B2 (en) | 2008-03-10 | 2014-10-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
KR101057485B1 (ko) | 2008-08-04 | 2011-08-17 | 서울대학교산학협력단 | 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물 |
WO2010128026A2 (en) | 2009-05-05 | 2010-11-11 | Givaudan Sa | Organic compounds |
JP2014516080A (ja) * | 2011-06-08 | 2014-07-07 | エスティーアイ ファーマ, エルエルシー | 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤 |
EP2757887B1 (en) * | 2011-09-22 | 2017-04-26 | VIIV Healthcare UK Limited | Pyrrolopyridinone compounds and methods for treating hiv |
RU2015128609A (ru) | 2012-12-19 | 2017-01-25 | КАШИВ ФАРМА, ЭлЭлСи | Перенасыщенные стабилизированные наночастицы для слаборастворимых лекарственных средств |
WO2015023889A1 (en) | 2013-08-16 | 2015-02-19 | Luminus Biosciences Inc. | Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease |
CN106029175A (zh) | 2014-02-27 | 2016-10-12 | 宝洁公司 | 具有减少的苦味感受的口腔护理组合物 |
WO2016207914A2 (en) | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for preparing oltipraz |
US20160376259A1 (en) * | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for Preparing Oltipraz |
ITUB20159655A1 (it) | 2015-12-23 | 2017-06-23 | Bormioli Rocco Spa | Capsula di sicurezza di un contenitore. |
ITUA20162141A1 (it) | 2016-03-31 | 2017-10-01 | Bormioli Pharma Spa | Capsula di chiusura |
JP2019531344A (ja) * | 2016-09-12 | 2019-10-31 | エスティー アイピー ホールディング エージー | 4−メチル−5−(ピラジン−2−イル)−3h−1,2−ジチオール−3−チオンの処方物、ならびにそれらの製造方法及び使用方法 |
KR20180123796A (ko) | 2017-05-10 | 2018-11-20 | 서울대학교산학협력단 | Nrf2-NEMO 경로 활성화를 통한 과중력으로 인한 세포괴사의 억제용 조성물 및 방법 |
-
2017
- 2017-09-12 BR BR112019004639A patent/BR112019004639A2/pt not_active IP Right Cessation
- 2017-09-12 JP JP2019535991A patent/JP2019533008A/ja active Pending
- 2017-09-12 CA CA3036630A patent/CA3036630A1/en active Pending
- 2017-09-12 KR KR1020197010518A patent/KR20190089851A/ko not_active Application Discontinuation
- 2017-09-12 AU AU2017322544A patent/AU2017322544B2/en not_active Expired - Fee Related
- 2017-09-12 EP EP17808566.8A patent/EP3509641A1/en active Pending
- 2017-09-12 CN CN201780069887.1A patent/CN109996563A/zh active Pending
-
2019
- 2019-03-12 US US16/351,122 patent/US11185544B2/en active Active
- 2019-03-12 PH PH12019500530A patent/PH12019500530A1/en unknown
-
2021
- 2021-10-25 US US17/509,965 patent/US20220296589A1/en not_active Abandoned
-
2023
- 2023-05-09 JP JP2023077049A patent/JP2023113634A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US11185544B2 (en) | 2021-11-30 |
CN109996563A (zh) | 2019-07-09 |
AU2017322544A1 (en) | 2019-05-02 |
PH12019500530A1 (en) | 2020-02-24 |
EP3509641A1 (en) | 2019-07-17 |
JP2023113634A (ja) | 2023-08-16 |
KR20190089851A (ko) | 2019-07-31 |
CA3036630A1 (en) | 2018-03-15 |
JP2019533008A (ja) | 2019-11-14 |
AU2017322544B2 (en) | 2022-06-02 |
US20220296589A1 (en) | 2022-09-22 |
US20190209557A1 (en) | 2019-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017013408A2 (es) | Compuestos bicíclicos heterocíclicos como agentes antituberculares. | |
CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
NZ742208A (en) | Topical pharmaceutical formulations for treating inflammatory-related conditions | |
BR112018008877A8 (pt) | inibidores de ret | |
MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CO2018000668A2 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx/ca | |
BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CO2018000631A2 (es) | Compuestos bicíclicos como inhibidores de atx | |
CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
BR112017012342A2 (pt) | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos | |
AU2017228405A8 (en) | Small molecule IRE1-alpha inhibitors | |
BR112015032736A2 (pt) | inibidores de bromodomínio cristalino | |
ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
MX2020006612A (es) | Compuesto que funciona como inhibidor de proteína de bromodominio y composición. | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
CL2019002251A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. | |
PL417066A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
BR112017025711A2 (pt) | ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras? | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
WO2018039475A8 (en) | Use of pridopidine for treating dystonias | |
BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2739 DE 04-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |